In conclusion, EGFR-TKI combined with radiotherapy has great potential in the treatment of advanced NSCLC, while for the incidence of radiation pneumonia in patients with advanced Adenocarcinoma of the lung treated by the first generation, second generation or third generation EGFR-TKI combined with chest radiotherapy, a study made a clinical and imaging comparison, and found that the incidence of radiation pneumonia in the first generation or third generation EGFR-TKI combined with chest radiotherapy was lower than that in the second generation EGFR-TKI combined with chest radiotherapy. The gene discussed is EGFR; the disease is radiation pneumonitis.